PRGO — Perrigo Company plc

Summary of Perrigo (PRGO) Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• CORE Net Sales: Declined 8.3% year-over-year, primarily due to softer consumption in the Self Care segment, particularly cough and cold products, and retailer inventory destocking.
• All In Net Sales: Decreased 7.2%.
• Adjusted CORE EPS: Reported at $0.40, above expectations, benefitting from tariff recovery and a lower effective tax rate.
• All In Adjusted EPS: $0.43, down $0.17 year-over-year.
• Cash Flow: Operating cash flow was an outflow of $114 million, a decrease of $49 million from the previous year.
• Goodwill Impairment: A noncash charge of $331 million was recorded due to the reallocation of goodwill following the new reporting structure.

2. Strategic Updates and Business Highlights:

• Three-S Plan: Focused on stabilizing, streamlining, and strengthening the company, with notable market share gains in U.S. store brand OTC products (up 270 basis points).
• Divestiture: Completed the sale of the Dermacosmetics business, with proceeds expected to support debt reduction.
• Cost Savings: Achieved over $7 million in cost savings in Q1, with a target of $60 million to $80 million for the year.
• Operational Enhancements: New category-led operating model implemented to align decision-making and investment priorities.
• Market Performance: Strong performance in women's health and nicotine replacement therapy, with significant share gains in multiple OTC categories.

3. Forward Guidance and Outlook:

• 2026 Outlook: Reaffirmed, expecting results to be weighted towards the second half of the year, driven by stabilizing category consumption and the easing of prior year manufacturing volume headwinds.
• Sales Growth Drivers: Anticipated growth from consumer-centric innovation, geographic expansion, and demand generation initiatives.
• EPS Expectations: Approximately 30% to 35% of CORE adjusted EPS expected in the first half, with 65% to 70% in the second half.

4. Bad News, Challenges, or Points of Concern:

• Market Environment: Continued challenges in the market, including a decline in the OTC market (U.S. down 4.1% in value) and European market pressures.
• Cough and Cold Demand: Softer demand for cough and cold products impacted sales, with expectations for recovery being uncertain.
• Inventory Destocking: Retailers reduced inventory levels, further hampering sales.
• Manufacturing Volume Headwinds: Carryover effects from prior year manufacturing issues expected to impact EPS by approximately $0.60 in 2026.

5. Notable Q&A Insights:

• Operating Margin Recovery: Management indicated that margin improvement in the second half will depend on both working through higher-cost inventory and a rebound in OTC volumes.
• Infant Formula Review: Strategic review ongoing, with focus on optimizing operations and potential partnerships or divestments.
• Consumer Behavior: E-commerce is driving higher shares for store brands, but there is room for improvement in representation and marketing strategies.
• Pricing Strategy: Active consideration of pricing adjustments in response to inflationary pressures, particularly in the context of rising commodity prices.

Overall, while Perrigo faced significant challenges in Q1 2026, the company is implementing strategic initiatives that are expected to drive long-term growth and improve financial performance in the latter half of the year.